We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Prospective, Randomized, Controlled, Un-blinded, Multi-Center Clinical Trial to Evaluate the HeartWare® Ventricular Assist System for Destination Therapy of Advanced Heart Failure (ENDURANCE)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01166347
First Posted: July 21, 2010
Last Update Posted: September 25, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
HeartWare, Inc.
July 16, 2010
July 21, 2010
September 25, 2017
August 2010
May 2014   (Final data collection date for primary outcome measure)
Stroke-free survival [ Time Frame: Two years ]
The primary endpoint of the trial is stroke-free survival at two years, defined as alive on the originally implanted device, transplanted or explanted due to patient recovery. Secondary endpoints include adverse events such as bleeding and infection, as well as functional status, hospitalization, assessment of neuro-cognitive function and patient quality of life.
Not Provided
Complete list of historical versions of study NCT01166347 on ClinicalTrials.gov Archive Site
  • Incidence of bleeding [ Time Frame: Two years ]
    Incidence of bleeding, per INTERMACS definition
  • Incidence of major infections [ Time Frame: Two years ]
    Incidence of major infections, per INTERMACS definition
  • Incidence of all device failures and device malfunctions [ Time Frame: Two years ]
    Incidence of all device failures and device malfunctions per INTERMACS definition
  • Time to death [ Time Frame: Two Years ]
  • Health Status improvement measured by KCCQ and EuroQol EQ-5D [ Time Frame: Two Years ]
    Health Status improvement as measured by Kansas City Cardiomyopathy Questionaire (KCCQ) and EuroQol EQ-5D.
  • Functional status improvement measured by (NYHA)class and 6-minute walk [ Time Frame: Two Years ]
    Functional status improvement, as measured by New York Heart Association (NYHA)class and 6-minute walk test.
Not Provided
Not Provided
Not Provided
 
A Prospective, Randomized, Controlled, Un-blinded, Multi-Center Clinical Trial to Evaluate the HeartWare® Ventricular Assist System for Destination Therapy of Advanced Heart Failure
A Prospective, Randomized, Controlled, Un-blinded, Multi-Center Clinical Trial to Evaluate the HeartWare® Ventricular Assist System (VAS) for Destination Therapy of Advanced Heart Failure
The purpose of this study is to determine the safety and effectiveness of the HeartWare Ventricular Assist System in patients with chronic Stage D/NYHA Class IIIB/IV left ventricular failure who have received and failed optimal medical therapy, and who are ineligible for cardiac transplantation.
The HeartWare Ventricular Assist System (VAS) is intended for use in patients with chronic Stage D/NYHA Class IIIB/IV left ventricular failure who have received and failed optimal medical therapy and who are ineligible for cardiac transplantation. The ENDURANCE clinical study is a prospective, randomized, unblinded, multi-center, non-inferiority evaluation of the HeartWare® VAS versus a control group consisting of any FDA-approved LVAD approved for destination therapy. Patients are randomized to HeartWare® VAS or control LVAD in a 2:1 ratio. Each patient receiving the HeartWare® VAS or control LVAD is followed to the primary endpoint at 2 years, with a subsequent follow-up period extending to 5 years post implant.
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Chronic Heart Failure
  • Device: HeartWare® VAS
    The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.
  • Device: Control LVAD
    Any FDA-approved LVAD for destination therapy.
  • Experimental: HeartWare® VAS
    Implant of HeartWare® Ventricular Assist System
    Intervention: Device: HeartWare® VAS
  • Active Comparator: Control LVAD
    Implant of FDA-approved LVADs approved for destination therapy
    Intervention: Device: Control LVAD
Rogers JG, Pagani FD, Tatooles AJ, Bhat G, Slaughter MS, Birks EJ, Boyce SW, Najjar SS, Jeevanandam V, Anderson AS, Gregoric ID, Mallidi H, Leadley K, Aaronson KD, Frazier OH, Milano CA. Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure. N Engl J Med. 2017 Feb 2;376(5):451-460. doi: 10.1056/NEJMoa1602954.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
451
May 2017
May 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Must be ≥18 years of age at consent
  2. Body Surface Area (BSA) ≥ 1.2 m2
  3. Patients with advanced heart failure symptoms (Class IIIB or IV) who are: (patient must meet one of the following) 3a. On optimal medical management, including dietary salt restriction and diuretics, for at least 45 out of the last 60 days and are failing to respond; or 3b. In Class III or Class IV heart failure for at least 14 days, and dependent on intra aortic balloon pump (IABP) for 7 days and/or inotropes for at least 14 days
  4. Left ventricular ejection fraction (less than or equal to) 25%
  5. LVAD implant is intended as destination therapy
  6. Must be able to receive either the HeartWare® VAS or control LVAD
  7. Female patients of childbearing potential must agree to use adequate contraceptive precautions for the duration of the study.
  8. The patient or legally authorized representative has signed the informed consent form

Exclusion Criteria:

  1. Body Mass Index (BMI) > 40
  2. Existence of any ongoing mechanical circulatory support (MCS) other than an intra-aortic balloon pump (IABP)
  3. Prior cardiac transplant.
  4. History of confirmed, untreated abdominal or thoracic aortic aneurysm > 5 cm.
  5. Cardiothoracic surgery within 30 days of randomization.
  6. Acute myocardial infarction within 14 days of implant
  7. Patients eligible for cardiac transplantation
  8. On ventilator support for > 72 hours within the four days immediately prior to randomization and implant.
  9. Pulmonary embolus within three weeks of randomization
  10. Symptomatic cerebrovascular disease, stroke within 180 days of randomization or > 80% stenosis of carotid or cranial vessels.
  11. Uncorrected moderate to severe aortic insufficiency. Correction may include repair or bioprosthesis at the time of implant.
  12. Severe right ventricular failure as defined by the anticipated need for right ventricular assist device (RVAD) support or extracorporeal membrane oxygenation (ECMO) or right atrial pressure > 20 mmHg on multiple inotropes, right ventricular ejection fraction (RVEF) <15% or clinical signs
  13. Active, uncontrolled infection diagnosed by a combination of clinical symptoms and laboratory testing.
  14. Uncorrected thrombocytopenia or generalized coagulopathy (e.g., platelet count < 75,000, INR > 2.0 or PTT > 2.5 times control in the absence of anticoagulation therapy).
  15. Intolerance to anticoagulant or antiplatelet therapies or any other peri- or postoperative therapy that the investigator may administer based upon the patient's health status.
  16. Serum creatinine > 3.0 mg/dL within 72 hours of randomization or requiring dialysis (does not include use of ultra-filtration for fluid removal).
  17. All three liver enzymes [AST (SGOT), ALT (SGPT), or LDH] > 3 times upper limit of normal or a total bilirubin > 3 mg/dl within 72 hours of randomization, or biopsy proven liver cirrhosis or portal hypertension.
  18. Pulmonary vascular resistance is demonstrated to be unresponsive to pharmacological manipulation and the PVR > 6 Wood units.
  19. Patients with a mechanical heart valve .
  20. Etiology of heart failure is due to, or associated with, uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis, active myocarditis or restrictive cardiomyopathy
  21. History of severe COPD or severe restrictive lung disease
  22. Participation in any other study involving investigational drugs or devices
  23. Severe illness, other than heart disease, which would limit survival to < 3 years
  24. Peripheral vascular disease with rest pain or ischemic ulcers of the extremities
  25. Pregnancy
  26. Patient unwilling or unable to comply with study requirements
  27. Technical obstacles, which pose an inordinately high surgical risk, in the judgment of the investigator
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01166347
HW004 ENDURANCE
Yes
Not Provided
Not Provided
HeartWare, Inc.
HeartWare, Inc.
Not Provided
Principal Investigator: Francis Pagani, MD University of Michigan Hospital
Principal Investigator: Joseph Rogers, MD Duke University
HeartWare, Inc.
September 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP